#### FOLETTA MARK G

Form 3

January 31, 2013

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

FOLETTA MARK G

(Last) (First) (Middle)

Statement (Month/Day/Year)

01/30/2013

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Regulus Therapeutics Inc. [RGLS]

4. Relationship of Reporting

Person(s) to Issuer

Filed(Month/Day/Year)

5. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check Applicable Line) \_X\_ Form filed by One Reporting

C/O REGULUS THERAPEUTICS INC., Â 3545 JOHN HOPKINS COURT.

**SUITE 210** 

(Street)

(Check all applicable)

10% Owner \_X\_ Director Officer Other (give title below) (specify below)

SAN DIEGO, CAÂ 92121

Form filed by More than One Reporting Person

(City) (State) (Zip)

1. Title of Security (Instr. 4)

Table I - Non-Derivative Securities Beneficially Owned 2. Amount of Securities

Beneficially Owned (Instr. 4)

0

Ownership Form:

4. Nature of Indirect Beneficial Ownership

Person

(Instr. 5)

Direct (D) or Indirect

(Instr. 5) D

Common Stock

Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying **Derivative Security** 

Ownership Conversion or Exercise

6. Nature of Indirect Beneficial Ownership

Form of (Instr. 5)

(Instr. 4) Price of Derivative Derivative Security: Date **Expiration Title** Amount or Direct (D) Security Exercisable Number of or Indirect Shares (I) (Instr. 5)

## **Reporting Owners**

Reporting Owner Name / Address

Director 10% Owner Officer Other

FOLETTA MARK G

C/O REGULUS THERAPEUTICS INC.
3545 JOHN HOPKINS COURT, SUITE 210

SAN DIEGO, CAÂ 92121

# **Signatures**

/s/ Mark G.
Foletta

\*\*Signature of Reporting Person

O1/31/2013

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. ="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;">(571) 434-5400 (Registrant's telephone number, including area code.)

(Former name and former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
he registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Reporting Owners 2

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Following the mutual decision of Mark F. Bregman and Neustar, Inc. (the "Company"), Dr. Bregman will depart the Company effective as of September 26, 2014. Based on the terms and conditions of his departure, Dr. Bregman will receive the severance benefits provided for under the Company's 2010 Key Employee Severance Plan, a copy of which was previously filed on July 28, 2010 as Exhibit 10.28 to the Company's Quarterly Report on Form 10-Q.

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NeuStar, Inc.

Date: September 15, 2014 By: /s/ Paul S. Lalljie

Name: Paul S. Lalljie

Title: Chief Financial Officer (Principal Financial and Accounting Officer and Duly Authorized Officer)